medRxiv: The world's first PD1 knockout virus-targeted integrated CART treatment for lymphoma has achieved breakthrough results.

On September 25, 2020, Shanghai Bangyao Biotech Co., Ltd. ("Bangyao Bio"), a company focused on gene therapy and cell drug research and development, announced a breakthrough in the clinical trial of "PD1 Knockout Virus Point Integration CD19-CART Cell Therapy Recurring Non-Hodgkin's Lymphoma" in collaboration with the First Hospital affiliated with Zhejiang University Medical College.
is the world's first cart treatment using gene editing technology to achieve fixed-point integration at PD1 locations, and the world's first clinical trial of non-viral targeted integrated CART cell therapy for lymphoma.
the same time, the latest research results were announced on September 23, 2020 on the preprint platform medRxiv, by East China Normal University, Zhejiang University School of Medicine affiliated with the first hospital and Shanghai Bangyao Bio.
CD19-CART integrated with PD1 is Quikin CART for Bangyao Bio using its own intellectual property rights? Platform technology, without the use of virus vectors, step-by-step preparation of obtained CART products.
the product combined PD1 immuno-checkpoint suppression with CART tumor killing function, which played a role in the combined application of PD1 immunotherapy and CART therapy.
2 patients were completely relieved of the clinical study group of 15 patients after 3 months of treatment, and 4 patients who can now be evaluated have achieved partial remission (PR) at 1 month, and 2 patients who have reached 3 months of assessment time have received full remission (CR).
first patient to receive complete remission was diagnosed with diffuse large B lymphoma IVBE in 2018, and after multiple chemotherapy treatments, the condition was not effectively controlled.
pre-entry imaging showed that the left lower abdominal small intestine walking area membrane gap size of 3.6 x 3.5 cm lesions, abnormally high radioactive intake.
May 2020 into the group for PD1 knock-on unless the virus targeted integration CD19-CART cell refractation treatment, 28 days after treatment PET-CT imaging shows that FDG metabolism significantly decreased, reached PR, 90 days after treatment PET-CT imaging showed that the lesions all disappeared, FDG metabolism did not increase, reached CR.
drug-related adverse events, including cytokine storms and neurotoxicity, did not occur throughout CART treatment.
, CART amplified well in the body and lasted a long time, and D90 fluid testing found that the CART cells in the outer blood remained at a certain proportion.
2 patients have recovered and been discharged from hospital and are still receiving long-term follow-up. "Diffuse large B-cell lymphoma is the most common non-Hodgkin's lymphoma, and there is currently a lack of effective treatment for patients with relapses," said HuangHe, director of the First Hospital affiliated with Zhejiang University School of Medicine in
.
This year we began exploring clinical studies of non-viral targeted integrated CART based on gene editing technology, and we are pleased to see patients rapidly reach full remission after treatment, and we expect this new CART technology to bring more convenient, safe and accurate long-term treatment to patients with relapses.
" BangYao BioCART Upgrade 2.0, more effective and safer! Bonyo Bio's non-viral fixed-point integrated CART technology (Quikin CART? ), using CRISPR/Cas9 gene editing technology to insert CAR components into specific site of the genome without the use of virus vectors, step by step to achieve the stable integration of gene knocking and CAR, belonging to Bangyao Bio 2.0 version of CART pipeline products.
PD-L1/PD1 is an important immune checkpoint to inhibit the function of T cells, the current inhibitors for PD-L1/PD1 have achieved good results in many types of malignant tumors, and many studies have reported that PD1 knock-out can effectively enhance the function of CART cells.
non-Hodgkin's lymphoma is a malignant tumor of the blood system that is native to lymphatic tissue, accounting for 80%-90% of all lymphomas, and although the disease is alleviated after initial treatment, it often relapses later.
Although CART products have been approved for clinical treatment of recurring recurring non-Hodgkin's lymphoma, the overall efficacy is still limited, and studies suggest that inhibiting the PD1 pathrapy may lead to better clinical outcomes.
, Bon Yew Bio uses Quikin CART? The platform developed non-viral PD1 fixed-point integrated CD19-CART cells to carry out clinical treatment of recurring recurring non-Hodgkin's lymphoma.
the product has two advantages of CAR stability expression and PD1 gene knock-out, which is equivalent to the strong combination of PD1 inhibitors and CART cells.
cart product demonstrated excellent safety and effectiveness in several clinical trials that have been conducted so far.
the preparation of traditional CART products mainly use virus vectors, the virus preparation process put forward high requirements, which greatly increased the cost and difficulty of CART cell manufacturing, hindering the large-scale clinical application of CART treatment; ymriah is priced at $475,000 and Kite's Yescarta is priced at $373,000, and because the virus integrates CAR components into the cell genome by random insertion, it can alter the expression of normal genes, potentially caused by cancer.
Quikin CART? The technology eliminates the need for cell preparation using viral vectors, greatly reducing the production cost of CART products while avoiding the risk of random insertion of cancer.
Quikin CART? The technology can simultaneously regulate the endotgen genes of T-cells and the continuous expression of CAR in just one step.
other CART technologies, the product has the advantages of simple process, fewer production links, short preparation time and high product ism.
The technology platform can be used for the preparation of multiple immune checkpoint knock-out enhanced CART cells, can quickly produce general purpose CART cells, can develop dynamic regulation of safe CART products, etc., for the future cart cell diversification provides a strong technical support.
Mingyao, chief scientist of bios at East China Normal University, said: "Compared to traditional in-house CART technology, Quikin CART? The technology can achieve the fixed-point integration of CAR elements in the genome and the regulatory intervention of T-cell endogenetic genes in one step without the use of viruses.
This means that THE cell preparation process, production process, preparation time will be greatly simplified and shortened, thus greatly reducing the production cost of CART cells, while reducing the risk of tumor caused by random insertion of viruses, but also improve the erration of CART products.
results show that our prepared non-viral PD1 targeted integrated CD19-CART cells have great therapeutic potential and show good safety and mitigation rates in clinical trials. "In recent years, the growing maturity and development of CRISPR/Cas9 gene editing technology has led us to the idea of applying it to CART therapy," said Dr. Zhang Yanqin, lead author of the
project and lead author of the paper, Director of Research and Development of Bangyao Bioinnovated CART, and Associate Research Fellow, School of Life Sciences, East China Normal University.
in-depth analysis of existing CART technologies, we realized that using gene editing techniques to prepare non-viral fixed-point integrated CART cells was a promising direction.
through a lot of methods to try and condition groping, we built a mature Quikin CART? Technology platform.
the technology does not require any viruses, cart cells can be prepared in just one step, with many advantages that existing CART technology is unmatched.
look forward to using this technology platform in the future to develop more successful CART products, in clinical treatment to achieve greater breakthroughs.
" it is known that in addition to the ongoing clinical study of non-viral PD1 fixed-point integration CD19-CART, Bangyao Bio is also layout other non-viral fixed-point integrated CART products for solid tumors, with a view to making greater breakthroughs in CART therapy.
About Bangyao Biological Shanghai Bangyao Biotech Co., Ltd. is committed to becoming the world's leading gene cell pharmaceutical company, Bangyao Bio with "gene editing to lead innovation, the development of breakthrough therapies for the benefit of all mankind" mission, relying on independent research and development center and jointly established with East China Normal University, "Shanghai Gene Editing and Cell Therapy Research Center", in the past five years has produced 108 patent results, 5 projects in 8 well-known hospitals to carry out IIT trials, including 3 projects into the IND filing stage, 12 high-level academic papers have been published in internationally renowned journals such as Nature Medicine.
Bangyao Bio has built three major technology platforms for gene editing, cell therapy and gene therapy, and has a pilot base of 6000 square meters of GMP and an operation team of nearly 100 people, effectively ensuring that innovative research results can be quickly transformed and applied.
Bio continues to drive rapid product update iterations through patient needs and clinical feedback.
Driven by the new era of commercial civilization, Bangyao Bio upholds an open, shared and win-win attitude, and together with the global innovative biopharmaceutical ecological chain enterprises, accelerate the transformation and landing of innovative drugs for the benefit of global genetic diseases and malignant tumor patients!